IONS vs RLMD
IONS: Ionis Pharmaceuticals is a pioneer in RNA-targeted therapies, transitioning into a commercial-stage biotech with a pipeline focused on neurology and cardiometabolic diseases. RLMD: Clinical-stage biotech redirecting toward oncology and neurology with in-licensed chemotherapy delivery and neurosteroid platforms after terminating its lead depression candidate.
Side-by-side fundamentals
| Metric | IONS | RLMD | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $55.96 | $5.20 | |
| Market cap as of 2026-08-03 | $9.3B | $545M | |
| PEG as of 2026-08-03 | -0.18 | n/a | |
| Net margin as of 2026-08-03 | -30.9% | -500.0% | IONS higher |
| Gross margin as of 2026-08-03 | +98.3% | +0.0% | IONS higher |
| Operating margin as of 2026-08-03 | -33.3% | -500.0% | IONS higher |
| ROE as of 2026-08-03 | -58.7% | -71.2% | IONS higher |
| ROA as of 2026-08-03 | -10.1% | -64.5% | IONS higher |
| Debt / equity as of 2026-08-03 | 4.76 | 0.00 | RLMD lower |
| Revenue growth (YoY) as of 2026-08-03 | +47.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +17.1% | n/a | |
| Beta as of 2026-08-03 | 0.38 | 0.48 | |
| 1-year return as of 2026-07-27 close | +32.4% | +703.7% | RLMD higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.